Tradestie Institutional Equity Comparison Engine

SRZN vs CING โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

SRZN Overall Edge

SRZN Captures Institutional Edge (3โ€“0 Pillars ยท 5โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Surrozen, Inc. Common (SRZN) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, SRZN trades at N/M Forward P/E with -485.4% operating margin (+408.6% YoY revenue) versus CING at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, SRZN sits in CONSOLIDATION (5th %ile IV; Dealer Gamma Walls on Pro) against CING sits in BREAKDOWN (16th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
SRZN N/M vs CING N/M Fwd P/E
Growth & Margin Winner SRZN
Op Margin -485.4% vs 0.0% ยท YoY +408.6% vs +0.0%
Momentum & Technical Winner SRZN
1Y +130.6% vs +35.4% ยท 52W Pos 69% vs 18%
Options & Structure Winner SRZN
CONSOLIDATION (5th %ile IV) vs BREAKDOWN (16th %ile IV)
SRZN NASDAQ
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$29.93
-7.38% 1D
Market Cap $602.5M
1M Return +25.57%
1Y Return +130.62%
Forward P/E N/M
Unified AI Score
33.2 / 100 SELL
Tech 50.0 Fund 34.0 Flow 65.0 Mom 40.0
CING NASDAQ
Cingulate Inc. Common Stock
Pharmaceutical Preparations
$4.72
+26.0% 1D
Market Cap $62.5M
1M Return +8.37%
1Y Return +35.39%
Forward P/E N/M
Unified AI Score
44.8 / 100 HOLD
Tech 31.0 Fund 50.0 Flow 67.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: SRZN +130.62% CING +35.39% Spread: +95.23 pp (SRZN Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
SRZN TTM Op. Margin: -485.4% CING TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SRZN vs CING. Trailing 12-month operating profitability (SRZN -485.4% vs CING 0.0%) and valuation multiples (SRZN N/M vs CING N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: SRZN (5) vs CING (2)
Institutional Metric SRZN CING Criterion Row Winner
Market Capitalization Scale $602.5M $62.5M Larger Scale SRZN
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +408.6% +0.0% Higher Growth SRZN
Operating Margin (TTM) Profitability -485.4% 0.0% Higher Margin CING
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -62.8% -198.7% Higher ROE SRZN
52-Week Range Position Momentum 69% ($12โ€“$38) 18% ($3โ€“$12) Stronger Trend SRZN
Beta / 30D Volatility Risk Regime 1.28ฮฒ ยท 66% Vol 1.07ฮฒ ยท 121% Vol Lower Realized Risk SRZN
Unified Institutional Score Composite Signal 33.2 / 100 (SELL) 44.8 / 100 (HOLD) Higher Composite CING

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full SRZN vs CING Buy Guide
SRZN CONSOLIDATION
38d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 5th %ile
IV Regime Compressed (<25th %ile)
Live SRZN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CING BREAKDOWN
170d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 16th %ile
IV Regime Compressed (<25th %ile)
Live CING Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither SRZN nor CING registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.